71.83

1.14% -0.83

Pre-market: 74.15 2.32 +3.23%

Astrazeneca PLC (AZN)

Overview News Price History Option Chain Why AZN Down? Discussions Forecast Stock Split Dividend History

Astrazeneca PLC stock is traded at $71.83, with a volume of 7.65M. It is down -1.14% in the last 24 hours and up +2.83% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Previous Close:

$72.66

Open:

$72.725

24h Volume:

7.65M

Relative Volume:

1.69

Market Cap:

$222.77B

Revenue:

$54.98B

Net Income/Loss:

$7.77B

P/E Ratio:

28.85

EPS:

2.49

Net Cash Flow:

$9.14B

1W Performance:

+4.53%

1M Performance:

+2.83%

6M Performance:

+3.22%

1Y Performance:

-8.06%

1-Day Range:

$71.49

$73.03

1-Week Range:

$69.42

$74.38

52-Week Range:

$61.24

$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name

Astrazeneca PLC

Sector

Healthcare (1164)

Industry

Drug Manufacturers - Major (1)

Phone

44 20 3749 5000

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge

Employee

61,100

Twitter

@AstraZeneca

Next Earnings Date

2024-11-12

Latest SEC Filings

AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AZN Astrazeneca PLC	71.83	225.28B	54.98B	7.77B	9.14B	2.49

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold
Dec-18-23	Initiated	HSBC Securities	Buy
Sep-25-23	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold
Mar-16-21	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Upgrade	UBS	Neutral → Buy
Jan-15-21	Initiated	Deutsche Bank	Buy
Dec-07-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-30-20	Upgrade	UBS	Sell → Neutral
Nov-11-20	Upgrade	HSBC Securities	Reduce → Hold
Sep-29-20	Initiated	Berenberg	Buy
Nov-22-19	Initiated	SVB Leerink	Outperform
Oct-25-19	Upgrade	Liberum	Hold → Buy
Apr-02-19	Downgrade	UBS	Neutral → Sell
Feb-05-19	Initiated	Exane BNP Paribas	Outperform
Jan-25-19	Upgrade	Shore Capital	Hold → Buy
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Aug-16-18	Downgrade	Jefferies	Buy → Hold
Mar-19-18	Upgrade	Jefferies	Hold → Buy
Feb-06-18	Reiterated	Leerink Partners	Mkt Perform
Feb-05-18	Reiterated	Bernstein	Outperform
Jan-18-18	Reiterated	Leerink Partners	Mkt Perform
Dec-29-17	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Upgrade	Credit Suisse	Neutral → Outperform
Sep-25-17	Upgrade	Exane BNP Paribas	Neutral → Outperform
Sep-22-17	Upgrade	Bernstein	Mkt Perform → Outperform

View All

Astrazeneca PLC Stock (AZN) Latest News

04:55 AM

Earnings Snapshot:AstraZeneca surpasses Q2 estimates;reaffirms FY outl - Seeking Alpha

04:55 AM

04:19 AM

FTSE 100 rises on lift from AstraZeneca results - MarketScreener

04:19 AM

03:44 AM

AstraZeneca's profit, revenue lifted by cancer drugs - The Edge Malaysia

03:44 AM

03:08 AM

FTSE 100 Live: Mixed start to trading, Games Workshop impresses, AstraZeneca and Barclays less so - Proactive Investors

03:08 AM

02:53 AM

AstraZeneca beats forecasts after record US growth - Financial Times

02:53 AM

02:51 AM

AstraZeneca maintains outlook as pipeline delivers strong late-stage results - Proactive Investors

02:51 AM

02:35 AM

Astrazeneca: Demand for cancer drugs boosts pharmaceutical giant - Yahoo.co

02:35 AM

02:34 AM

FTSE 100 Live: London stocks set to rebound as AstraZeneca, Barclays, Entain report By Proactive Investors - Investing.com UK

02:34 AM

02:28 AM

Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN - ACCESS Newswire

02:28 AM

02:26 AM

FTSE 100 Live: London stocks set to rebound as AstraZeneca, Barclays, Entain report - Proactive Investors

02:26 AM

02:25 AM

AstraZeneca Profit, Revenue Lifted by Cancer Drugs - Bloomberg

02:25 AM

02:13 AM

AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion - MSN

02:13 AM

02:10 AM

AstraZeneca beats second-quarter profit expectations, maintains outlook - Reuters

02:10 AM

02:06 AM

AstraZeneca beats second-quarter profit expectations - MarketScreener

02:06 AM

02:05 AM

AstraZeneca beats profit expectations on robust drug sales, U.S. demand - Yahoo.co

02:05 AM

01:37 AM